Skip to main content
Fig. 5 | BMC Biotechnology

Fig. 5

From: Microvesicles-delivering Smad7 have advantages over microvesicles in suppressing fibroblast differentiation in a model of Peyronie’s disease

Fig. 5

Effects of MVs or Smad7-MVs treatment on the changes of pathology in the TA of rats. 50 µL TGF-β1 (0.5 µg) were injected into the right midshaft dorsomedial TA. After injection one day, the TA was injected with 50 µL (50 µg) MVs or Smad7-MVs. The changes of pathology of TA were observed using H&E (A) and Masson (B). Scale = 100 μm. Black arrow: inflammatory factor. *p < 0.05, **p < 0.01

Back to article page